Semaglutide Explored as Novel Treatment for Cocaine Use Disorder
Background
The United States faces a critical public health crisis with a resurgence in cocaine use and associated mortality. Despite the significant burden, there are currently no FDA-approved pharmacotherapies specifically for Cocaine Use Disorder (CUD). Existing behavioral interventions, such as cognitive behavioral therapy (CBT), demonstrate only modest efficacy when used alone, highlighting an urgent need for more effective treatment strategies. This pilot mechanistic study aims to identify if Semaglutide, a GLP-1 receptor agonist, can enhance the effectiveness of CBT for CUD.
Results
This is a recruiting clinical trial, therefore no results are available yet. However, the study aims to determine if Semaglutide significantly reduces cocaine use and cravings compared to placebo when combined with CBT. Researchers hypothesize that Semaglutide will lead to a measurable decrease in self-reported cocaine use and an improvement in addiction severity scores. Secondary objectives include assessing the impact of Semaglutide on craving intensity and identifying potential neurobiological mechanisms involved in its effects. > The primary objective is to evaluate the efficacy of Semaglutide in reducing cocaine use and improving treatment outcomes for individuals with Cocaine Use Disorder.
Why It Matters
The resurgence of cocaine use and related mortality underscores an urgent, unmet need for effective treatments. If Semaglutide proves effective in this pilot study, it could offer a novel pharmacological approach to Cocaine Use Disorder, potentially enhancing the success rates of behavioral therapies like CBT and providing hope for patients. This research could pave the way for the first FDA-approved pharmacotherapy for CUD, significantly improving public health outcomes and reducing the burden of addiction. Future steps would involve larger Phase II and Phase III human trials to confirm efficacy and safety across diverse populations.